MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process

被引:33
作者
Dong, Ying [1 ]
Jin, Xintian [2 ]
Sun, Zhiqiang [3 ]
Zhao, Yueming [4 ]
Song, Xianjing [5 ]
机构
[1] Tumor Hosp Jilin Prov, Dept Radiotherapy, Changchun 130021, Peoples R China
[2] Tumor Hosp Jilin Prov, Dept Thorac, Changchun 130021, Peoples R China
[3] Tumor Hosp Jilin Prov, Dept Invas Technol, Changchun 130021, Peoples R China
[4] Tumor Hosp Jilin Prov, Dept Oncol, Changchun 130021, Peoples R China
[5] Jilin Univ, Hosp 2, Dept Cardiol, Changchun 130041, Peoples R China
关键词
cdc42; EMT; migration; MiR-186; NSCLC; CELL-PROLIFERATION; 3RD-LINE TREATMENT; CANCER; EXPRESSION; MICRORNAS; INVASION; MIR-B-10;
D O I
10.14348/molcells.2017.2291
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study, qRT-PCR was employed to identify that miR-186 expression level in NSCLC tissues are highly associated with lymph node metastasis. In addition, through the application of western blotting, luciferase assay and qRT-PCR, it was found that miR-186 targeted 3. UTR of cdc42 mRNA and down-regulated cdc42 protein level in a post-transcriptional manner. Transwell assay indicated that cdc42 partially reversed the effect of miR-186 mimics. Besides, miR-186 was proved to regulate EMT by influencing biomarkers of this process and cell adhesion ability. Thus, miR-186 is a potential target for NSCLC therapy. miR-186 is proposed to be one of tumor-suppressors and may serve as a therapeutic target in NSCLC treatment.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 19 条
[1]   The leading edge during dorsal closure as a model for epithelial plasticity: Pak is required for recruitment of the Scribble complex and septate junction formation [J].
Bahri, Sami ;
Wang, Simon ;
Conder, Ryan ;
Choy, Juliana ;
Vlachos, Stephanie ;
Dong, Kevin ;
Merino, Carlos ;
Sigrist, Stephan ;
Molnar, Cristina ;
Yang, Xiaohang ;
Manser, Edward ;
Harden, Nicholas .
DEVELOPMENT, 2010, 137 (12) :2023-2032
[2]   miR-186 in Alzheimer's disease: a big hope for a small RNA? [J].
Ben Halima, Saoussen ;
Siegel, Gabriele ;
Rajendran, Lawrence .
JOURNAL OF NEUROCHEMISTRY, 2016, 137 (03) :308-311
[3]   MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42 [J].
Chou, Jinjiang ;
Wang, Bingyu ;
Zheng, Tianjing ;
Li, Xiaoman ;
Zheng, Lufeng ;
Hu, Jinhang ;
Zhang, Yan ;
Xing, Yingying ;
Xi, Tao .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 472 (01) :262-269
[4]   Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer [J].
de Marinisa, Filippo ;
Grossi, Francesco .
ONCOLOGIST, 2008, 13 :14-20
[5]   Cdc42 - the centre of polarity [J].
Etienne-Manneville, S .
JOURNAL OF CELL SCIENCE, 2004, 117 (08) :1291-1300
[6]   Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial [J].
Hornberger, John ;
Hirschc, Fred R. ;
Li, Qianyi ;
Page, Ray D. .
LUNG CANCER, 2015, 88 (02) :223-230
[7]   Global Patterns of Cancer Incidence and Mortality Rates and Trends [J].
Jemal, Ahmedin ;
Center, Melissa M. ;
DeSantis, Carol ;
Ward, Elizabeth M. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (08) :1893-1907
[8]   Targeting MicroRNAs in Cancer Gene Therapy [J].
Ji, Weidan ;
Sun, Bin ;
Su, Changqing .
GENES, 2017, 8 (01)
[9]   The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma [J].
Jikuzono, Tomoo ;
Kawamoto, Masashi ;
Yoshitake, Hiroshi ;
Kikuchi, Kunio ;
Akasu, Haruki ;
Ishikawa, Hitoshi ;
Hirokawa, Mitsuyoshi ;
Miyauchi, Akira ;
Tsuchiya, Shinichi ;
Shimizu, Kazuo ;
Takizawa, Toshihiro .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 42 (06) :1858-1868
[10]   Regulation of Collagen V Expression and Epithelial-Mesenchymal Transition by miR-185 and miR-186 during Idiopathic Pulmonary Fibrosis [J].
Lei, Guang-Sheng ;
Kline, Hannah L. ;
Lee, Chao-Hung ;
Wilkes, David S. ;
Zhang, Chen .
AMERICAN JOURNAL OF PATHOLOGY, 2016, 186 (09) :2310-2316